179 related articles for article (PubMed ID: 30015690)
1. Management of nonmetastatic castration-resistant prostate cancer.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):366-371. PubMed ID: 30015690
[TBL] [Abstract][Full Text] [Related]
2. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
3. Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Schultz NM; Janjan N; George DJ
Future Oncol; 2023 Oct; 19(31):2075-2082. PubMed ID: 37646326
[TBL] [Abstract][Full Text] [Related]
4. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
6. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
Saad F; Bögemann M; Suzuki K; Shore N
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):323-334. PubMed ID: 33558665
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.
Arnold P; Penaloza-Ramos MC; Adedokun L; Rees S; Lockhat M; Spary L; Watkins A; Gnanapragasam V; Crabb SJ
Sci Rep; 2021 Nov; 11(1):22151. PubMed ID: 34772971
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
10. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
11. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
13. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
[TBL] [Abstract][Full Text] [Related]
15. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
[TBL] [Abstract][Full Text] [Related]
16. Current treatment of non-metastatic castration-refractory prostate cancer.
Büchler T
Klin Onkol; 2021; 34(3):185-191. PubMed ID: 34362254
[TBL] [Abstract][Full Text] [Related]
17. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ; Michaelson MD
Oncologist; 2012; 17(2):288-90. PubMed ID: 22267850
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
19. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
20. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
